🤖 Wizey vs DeepSeek R1 — Does AI Reasoning Help With Lab Interpretation?

When DeepSeek released its R1 reasoning model in early 2025, it shook the AI industry. Open weights under an MIT license, prices an order of magnitude below closed US competitors, and a visible chain-of-thought (CoT — the model “thinking out loud” before answering) with math performance on par with OpenAI’s closed reasoning systems. Our engineering team spent weeks stress-testing it to answer one question: does this architecture actually belong in a medical AI pipeline?

The DeepSeek family has grown since then. By spring 2026 the lineup includes DeepSeek V4 with a hybrid reasoning mode and a 1M-token context window, V3.2-Speciale (gold medal at IMO 2025), and a compact R2 at 32B parameters that runs on a single consumer GPU. The technology is genuinely impressive. But “impressive technology” and “appropriate for medicine” are not the same claim.

In this article I walk through the engineering specifics of DeepSeek R1 and its successors: how reasoning is trained, where open weights change the game, why chain-of-thought is a double-edged sword in clinical contexts, and how Wizey’s structured pipeline compares. For the basics of how generalist LLMs handle lab reports — RAG, Lost in the Middle, hallucinations, HIPAA/GDPR — see our pillar piece on Wizey vs ChatGPT for medical AI.

What makes DeepSeek R1 architecturally different

The headline difference is reasoning. A standard LLM goes “prompt → answer”. R1 first generates a long internal chain-of-thought — often 2,000 to 10,000 tokens — and only then emits the final answer. You can see this directly in the API: a <think> block shows the model deliberating like a teacher working a problem on a whiteboard.

Under the hood, R1 is built on DeepSeek V3 with a Mixture of Experts (MoE) backbone. The model holds many specialized “sub-models” and routes each query to only the subset it needs, which is how you get hundreds of billions of total parameters at moderate inference cost. The reasoning ability itself was not trained by classical supervised fine-tuning but through reinforcement learning with GRPO (Group Relative Policy Optimization), described in the original DeepSeek R1 paper on arXiv and later published in Nature. Simplifying: the model was not taught the “right answers” — it was rewarded for reaching right answers, and it discovered strategies like self-checking, hypothesis enumeration, and backtracking on its own.

The second structural difference is open weights. Every DeepSeek release (V3, R1, V3.2, V4, R2) is published on Hugging Face under an MIT license. Any company can download the weights, run them on its own infrastructure, fine-tune them for a specific task, and pay nothing to the vendor for inference. For closed frontier models (GPT, Claude, Gemini) this is architecturally impossible.

Where open weights genuinely win: privacy and on-premise deployment

Open weights are not marketing rhetoric — they change the economics and the compliance story. This is the place where I think DeepSeek is strongest, and where mainstream coverage tends to underplay the implications.

In the cloud flow — chat.deepseek.com or the API — privacy looks the same as any other provider: your data goes to DeepSeek’s servers under Chinese data protection law. For US or European medical data that is a hard stop: neither HIPAA nor GDPR tolerate uncontrolled cross-border processing of protected health information.

Open weights change the picture entirely. You can deploy the model on your own hardware — a hospital data center, a research lab, even a physician’s workstation — and no byte of the patient record ever leaves your perimeter. Practical hardware targets:

• DeepSeek-R1-Distill-Llama-8B (distilled — a smaller model trained to imitate the large one): about 6 GB VRAM, runs on an RTX 3060 or better.
• DeepSeek-R1-Distill-32B: roughly 20 GB VRAM — RTX 3090, RTX 4090, or a server-grade T4/A10.
• DeepSeek-R1-Distill-70B: around 40 GB VRAM — two RTX 4090s or one A100.
• Full DeepSeek-R1 (671B MoE): a multi-H100/A100 server with 1+ TB of aggregate memory. Unrealistic for a home lab, ordinary for a clinical data center.
• R2 at 32B: fits on a single consumer RTX 4090 (24 GB VRAM) while approaching frontier quality.

Compare that to closed frontier models: for GPT-5 or Claude Opus you cannot “download the model” at all — every request must hit the vendor’s cloud. With DeepSeek you can install Ollama or vLLM on a server inside your network, plug in a local front-end, and keep the entire workflow air-gapped. That is the only practical path to running a world-class LLM while fully respecting HIPAA and GDPR — and it is a real advantage for hospital IT teams evaluating medical AI.

Inside Wizey we tested distilled R1 variants as part of an internal research track. Quality is lower than flagship closed models, but for well-scoped tasks — anonymized preprocessing, internal summarization — the local model is a working tool.

Where DeepSeek beats closed frontier models

To avoid a one-sided write-up: R1 and its successors are not a “cheap GPT clone.” On several dimensions they are objectively strong.

• Cost. Current DeepSeek V4 pricing is roughly an order of magnitude below the top OpenAI and Anthropic tiers. For high-volume workloads this is the difference between a product that ships and one that doesn’t.
• Math and formal logic. On AIME, MATH-500, SWE-bench and GPQA Diamond, R1/R2 match OpenAI’s reasoning models. For medicine this matters: eGFR calculations, weight-based dosing, unit conversions — these are math tasks where CoT genuinely helps.
• Reasoning transparency. The CoT trace is returned to the caller, so you can audit where the logic went off the rails. OpenAI’s o-series models hide reasoning behind the API.
• Fine-tunability. Because the weights are open, medical research groups can continue pre-training and RLHF on verified clinical corpora. That is structurally impossible for closed models.

These are real wins. The question is whether they add up to a clinical-grade tool, and that is where the story gets complicated.

Reasoning vs hallucination: does chain-of-thought help in medicine

This is the core question of the article and where I have the most mixed feelings as an engineer.

The good news. The large 2025 study “Medical Hallucinations in Foundation Models” found that chain-of-thought reduced medical hallucination rates in 86% of tested cases. On average, explicit reasoning does make the answer more accurate. R1 posted solid baseline results for hallucination resistance — better than most prior-generation models.

The bad news. CoT also obscures the hallucination signal. Classical detection methods — token-level confidence, output entropy — stop working well, because the model writes fluent, internally coherent text even when the conclusion is wrong. The limitations analysis of ChatGPT in clinical settings from The Lancet Digital Health already showed that narrative confidence is a poor proxy for medical truthfulness. Reasoning models amplify this.

The really bad news. Analyses of AI hallucinations in 2025 converge on a specific finding: language models are roughly 34% more likely to use confident phrasing (“definitely”, “without doubt”, “clearly”) precisely when they are wrong. Reasoning models make this worse: a long, thoughtful-looking trace makes the final answer feel more authoritative even when the CoT goes off course on step 3 and then walks coherently in the wrong direction for another 2,000 tokens.

In medicine this is the critical failure mode. Imagine: the model “reasons” 3,000 tokens about your elevated alkaline phosphatase, builds an elegant differential around possible causes, and concludes with osteomalacia — because on step 3 of the CoT it mixed up the adult reference range with the pediatric one. The output reads like a consulting physician’s note. It is wrong. Without CoT the same model might have given a vaguer, less confident answer — and a patient would more likely follow up rather than anchor on the conclusion.

The trade-off is real: reasoning lowers the average hallucination rate but raises the persuasiveness of the hallucinations that remain. For pure technical tasks (math, code) that is an acceptable exchange. For medicine the cost of an error is asymmetric, and that changes the calculus.

Scenario test: the same lab panel through R1 vs Wizey

Concretely — a scenario I ran during the technical evaluation.

The panel: a real (de-identified) comprehensive metabolic + CBC + ferritin + TSH + free T4 + CRP + homocysteine + vitamin D + B12 + lipid panel, 47 markers total. Several abnormalities: ferritin elevated at 320 ng/mL, CRP moderately elevated at 8.5 mg/L, TSH near the upper limit at 4.1 mIU/L, homocysteine 14 µmol/L.

DeepSeek R1 via chat interface (English, the model’s strongest language):

1. CoT of about 4,500 tokens, walking through each marker and building associations.
2. Final conclusion: flagged ferritin as “possible iron overload or chronic inflammation”, correctly linked it to CRP, but proposed hemochromatosis as a first-line differential (a rare genetic condition) on a single ferritin value.
3. Interpreted TSH 4.1 as “within normal range”, missing that 4.1 with borderline homocysteine and inflammation warrants an anti-TPO antibody workup and a repeat in 6–8 weeks — the standard subclinical hypothyroidism workup.
4. Homocysteine 14 was not flagged as needing attention (many labs use < 10 as optimal).
5. The model repeatedly added “consult a healthcare provider” boilerplate, but between those disclaimers issued very specific hypotheses in a confident tone.

The same panel through the Wizey pipeline:

1. All 47 markers parsed into a structured table against age- and sex-specific reference ranges.
2. Ferritin with elevated CRP interpreted correctly: rule out inflammation first (acute-phase reactant behavior), then consider iron overload. Hemochromatosis is only raised after confirmatory transferrin saturation and genetic testing — not from a single ferritin value.
3. TSH 4.1 highlighted as borderline with an explicit recommendation to retest with anti-TPO antibodies.
4. Homocysteine 14 flagged as mildly elevated with the B12/folate/B6 pathway and a suggestion to check those cofactors.
5. Every statement is bound to a specific source in the medical knowledge graph (clinical guidelines, NCBI StatPearls references for acute-phase reactants, Nature Medicine reviews).

The difference is not that DeepSeek is “dumber” — it is a capable model. The difference is that a generalist reasoning model has no built-in guardrails for unit conversion, reference-range selection, or a Bayesian hierarchy of diagnostic hypotheses. It reasons. Wizey follows protocols — and uses reasoning only where a verified protocol says reasoning is appropriate.

When DeepSeek R1 is the right tool

I want to be fair. Several scenarios where DeepSeek — especially locally deployed — is genuinely the right choice:

• Air-gapped clinical or R&D environments. If your organization has hard privacy requirements, a local R1-Distill-32B or R2 on your own server gives near-frontier quality without sending a single byte to a third party. This is the most practical path to HIPAA/GDPR compliance with a state-of-the-art LLM.
• Base for domain fine-tuning. Open weights let medical research groups continue pre-training on validated clinical corpora and build their own RLHF stacks. That option does not exist for closed models.
• Technical subtasks inside a medical pipeline. Dose calculations, unit conversion, risk scores like CHA2DS2-VASc or Wells — isolated math/logic modules where reasoning helps. Use it as a component, not as the “doctor.”
• Translation and terminology explanation — at this the model is on par with frontier systems.
• Cost-sensitive workloads — if you need to run millions of requests, the price delta versus closed frontier models becomes tens of thousands of dollars per month.

What I would not do: paste a real patient’s lab PDF into the cloud DeepSeek chat and treat the output as a clinical answer. Between the cross-border data flow, the persuasive-but-wrong CoT failure mode, the absence of medical-device certification, and the lack of reference-range discipline, this is a bad fit for the consumer use case. For a patient who wants to “send the lab to a bot and get an answer”, a purpose-built medical service is the right tool.

How Wizey uses reasoning — inside a protocol, not instead of one

The question I get most often: does Wizey also use reasoning internally? Yes — but constrained. Our pipeline looks like this:

1. OCR and extraction. Every value on the PDF is parsed deterministically and mapped to a structured schema (LOINC-style) with its lab-specific reference range.
2. Reference-range binding. Each value is evaluated against the correct range for the patient’s age, sex, and (where relevant) pregnancy or renal status. This is code, not LLM output.
3. RAG over a validated clinical knowledge graph. Every statement in the final report is grounded in a specific source — guideline, peer-reviewed paper, StatPearls entry — not free generation.
4. Reasoning for diagnostic chains, inside guardrails. This is where CoT-style thinking earns its keep: building a Bayesian differential where the prior and likelihood come from the knowledge graph, not from the model’s opinion.
5. Protocol-locked outputs. The final text is bound to the structured result. The model does not get to invent a diagnosis the protocol did not sanction.

That architecture does two things at once. It captures the genuine upside of reasoning — stepwise diagnostic logic, unit-safe calculations, awareness of co-variation between markers — while cutting off the specific failure mode that makes a pure reasoning model risky in medicine: a long, persuasive, internally consistent chain of thought that is wrong because the premises were never verified.

Conclusion

DeepSeek is technically impressive work, and I am genuinely glad the industry has an open-source alternative to closed frontier models. Local deployment unlocks privacy and fine-tuning options that closed-model users simply do not have, and that matters for hospitals, research groups, and anyone serious about data sovereignty.

But reasoning on its own does not solve the medical problem. A long, well-formed chain of thought on wrong premises is still a wrong answer — just better packaged. For the job of reading a specific patient’s labs, where every number, every reference range, and every differential matters, the Wizey team took a different route: a specialized pipeline with RAG over verified clinical sources and hard protocol guardrails. For the patient, that translates to one concrete promise — every statement in the report can be shown to a physician and traced back to a source.